131 related articles for article (PubMed ID: 20456634)
1. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun SC; Deshpande M; Rhodes G; Miller MD
J Viral Hepat; 2011 May; 18(5):338-48. PubMed ID: 20456634
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Kuntzen T; Timm J; Berical A; Lennon N; Berlin AM; Young SK; Lee B; Heckerman D; Carlson J; Reyor LL; Kleyman M; McMahon CM; Birch C; Schulze Zur Wiesch J; Ledlie T; Koehrsen M; Kodira C; Roberts AD; Lauer GM; Rosen HR; Bihl F; Cerny A; Spengler U; Liu Z; Kim AY; Xing Y; Schneidewind A; Madey MA; Fleckenstein JF; Park VM; Galagan JE; Nusbaum C; Walker BD; Lake-Bakaar GV; Daar ES; Jacobson IM; Gomperts ED; Edlin BR; Donfield SM; Chung RT; Talal AH; Marion T; Birren BW; Henn MR; Allen TM
Hepatology; 2008 Dec; 48(6):1769-78. PubMed ID: 19026009
[TBL] [Abstract][Full Text] [Related]
3. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
4. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
[TBL] [Abstract][Full Text] [Related]
5. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
[TBL] [Abstract][Full Text] [Related]
6. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
7. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.
Flores MV; Strawbridge J; Ciaramella G; Corbau R
Biochim Biophys Acta; 2009 Oct; 1794(10):1441-8. PubMed ID: 19505593
[TBL] [Abstract][Full Text] [Related]
8. Novel robust hepatitis C virus mouse efficacy model.
Zhu Q; Oei Y; Mendel DB; Garrett EN; Patawaran MB; Hollenbach PW; Aukerman SL; Weiner AJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3260-8. PubMed ID: 17005803
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
[TBL] [Abstract][Full Text] [Related]
10. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
Herrmann E; Zeuzem S; Sarrazin C; Hinrichsen H; Benhamou Y; Manns MP; Reiser M; Reesink H; Calleja JL; Forns X; Steinmann GG; Nehmiz G
Antivir Ther; 2006; 11(3):371-6. PubMed ID: 16759054
[TBL] [Abstract][Full Text] [Related]
11. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
[TBL] [Abstract][Full Text] [Related]
12. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
13. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
[TBL] [Abstract][Full Text] [Related]
15. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
[TBL] [Abstract][Full Text] [Related]
16. Virology: fresh assault on hepatitis C.
Rice CM
Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
[No Abstract] [Full Text] [Related]
17. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.
Hinrichsen H; Benhamou Y; Wedemeyer H; Reiser M; Sentjens RE; Calleja JL; Forns X; Erhardt A; Crönlein J; Chaves RL; Yong CL; Nehmiz G; Steinmann GG
Gastroenterology; 2004 Nov; 127(5):1347-55. PubMed ID: 15521004
[TBL] [Abstract][Full Text] [Related]
18. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
19. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
